Genelux Corporation (GNLX) today announced encouraging interim data showing partial responses of up to 85% tumor shrinkage in platinum-relapsed small cell lung cancer patients treated with systemically administered Olvi-Vec immunochemotherapy.
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) remain among the most aggressive malignancies, with limited options once patients relapse after platinum-based regimens. Current therapies often fail to provide durable benefits, underscoring the need for novel approaches.
The ongoing Phase 1b/2 SCLC trial, conducted in China, reported a 33% overall response rate (3/9 patients), including two partial responses in the highest dose cohort with tumor reductions of approximately 55% and approximately 85%. Disease control was achieved in 67% of patients, with exploratory durability signals showing progression-free survival extending beyond prior treatment lines. In parallel, the U.S.-based Phase 2 VIRO-25 trial in NSCLC demonstrated a 60% disease control rate in early cohorts, with Olvi-Vec generally well tolerated across both studies.
Olvi-Vec (olvimulogene nanivacirepvec), Genelux's lead investigational oncolytic immunotherapy, is designed to remodel the tumor microenvironment and resensitize tumors to platinum-based chemotherapy.
The company is advancing systemic dosing regimens to support future registrational trials in lung cancer, while also progressing its pivotal Phase 3 OnPrime/GOG-3076 trial in platinum-resistant ovarian cancer, with topline data expected in the second half of 2026.
Upcoming milestones:
•Additional interim lung cancer data readouts expected throughout 2026
•Topline results from the Phase 3 ovarian cancer trial anticipated in H2 2026.
•Continued enrolment in systemic Olvi-Vec trials to optimize efficacy and tolerability.
The company ended September 30, 2025, with cash, cash equivalents, short-term investments, and restricted cash totaling approximately $21 million, expected to provide runway into the third quarter of 2026 as it advances Olvi-Vec across multiple solid tumor indications.
GNLX has traded between $1.98 and $8.53 over the past year. The stock is currently trading at $4.40, down 3.18%
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.